Summary:
SYNHOX: Clinical Trial for Kidney Stone Prevention
Recurring kidney stones are not just painful, frustrating, and limiting. Over time, they can also be damaging to your long-term kidney health. If you are suffering from recurring kidney stones, the SYNHOX Study may be an option for you.
The SYNHOX Study is evaluating the safety of a potential new treatment option for hyperoxaluria (HOX), a condition that can cause kidney stones and kidney disease in some people who have undergone bariatric surgery.
We are enrolling people aged 18–74 who have had bariatric surgery more than one year ago for this phase 1 clinical study (additional eligibility criteria will apply).
Study duration: Approximately 6 months
All study participants receive at no cost:
- The investigational drug
- Ability to attend study visits in person, or, if more convenient, remotely at their home with a home health professional
- All study-related tests and assessments
The investigational drug: SYNB8802
- Modified probiotic designed to consume oxalate in the gastrointestinal tract and potentially prevent kidney stones and kidney damage due to HOX
- Oral solution
- Taken up to 3 times per day with meals